Current label evidence
Ozempic reports a grouped local-reaction rate, not a burning rate
The current Ozempic prescribing information, revised May 2026, identifies Ozempic as semaglutide injection for subcutaneous use. In placebo-controlled trials, injection-site reactions were reported in 0.2% of Ozempic-treated patients, with injection-site discomfort and erythema listed as examples. The label does not isolate burning or stinging, provide a placebo percentage in that passage, or establish an expected onset, intensity, size, or duration for a burning sensation.
- Do not say that 0.2% of Ozempic patients experienced burning; 0.2% is the grouped injection-site-reaction rate.
- Discomfort may include different patient descriptions, but the label does not define every report of burning as an expected Ozempic reaction.
- A trial rate cannot determine whether one symptom reflects medication, skin irritation, a needle or device issue, allergy, infection, tissue injury, or another cause.
Describe the symptom
Burning alone does not show whether a reaction is minor or urgent
A brief localized sting can look very different from persistent burning with expanding redness, increasing warmth, severe pain, swelling, drainage, fever, or skin-color change. Serious hypersensitivity reactions, including anaphylaxis and angioedema, are described in current Ozempic labeling. MedlinePlus lists rash, itching, fainting or dizziness, swelling of the eyes, face, mouth, tongue, or throat, and difficulty breathing or swallowing among symptoms that require immediate medical attention. A symptom list or photo cannot diagnose allergy, cellulitis, abscess, contact irritation, or tissue injury.
- Document when the sensation began, how long it lasted, whether it recurs, whether the border is spreading, and what other local or whole-body symptoms occurred.
- Tell the clinician about prior injection reactions, allergies, eczema or other skin disease, diabetes, immune suppression, circulation problems, and medicines that affect bleeding or immunity.
- Persistent, recurrent, worsening, spreading, unusually painful, or treatment-limiting burning deserves clinical review even when an online forum calls it normal.
Product and exposure check
Review the exact Ozempic pen, site, supplies, and skin exposures
Current Ozempic instructions identify the abdomen, thigh, or upper arm as subcutaneous injection areas and direct patients to rotate sites and avoid using the same site for Ozempic and insulin. They also warn against injecting into a muscle or vein and against sharing a pen, even if the needle is changed. A burning review should confirm whether the patient followed the instructions supplied with the exact pen without turning a symptom page into a substitute injection tutorial.
- Preserve the product name, strength, pen and carton labels, lot and refill details, needle or supply information, storage history, and any visible product or packaging change.
- Report whether the skin was already red, swollen, bruised, scarred, hardened, infected, recently shaved, or exposed to a new alcohol prep, adhesive, bandage, cleanser, lotion, or topical medicine.
- Do not repeat, increase, split, retime, change sites, change needles, or use another injection as a test without guidance from the responsible prescriber or pharmacist.
Compounded-product boundary
An Ozempic reaction rate does not transfer to compounded semaglutide
Ozempic is an FDA-approved finished semaglutide injection with a product-specific pen and prescribing label. A patient-specific compounded semaglutide prescription is not FDA-approved as a finished drug product and may differ in concentration, inactive ingredients, presentation, container, supplies, storage directions, and beyond-use date. The Ozempic 0.2% grouped rate therefore cannot be used as the expected rate for a compounded vial or another semaglutide product.
- Confirm whether the exposure was Ozempic, another approved brand, or a compounded prescription before applying any label evidence.
- For a compounded product, preserve the patient label, dispensing-pharmacy details, active ingredient, concentration, inactive ingredients when available, refill or lot information, storage history, and adverse-event contact.
- Avoid research-use vials, counterfeit pens, unlabeled mixtures, no-prescription sellers, copied syringe conversions, and claims that burning proves potency or absorption.
Escalation
Separate prescriber follow-up from infection and allergy emergencies
A mild stable symptom may be appropriate for prescriber follow-up, but rapidly spreading redness or swelling, severe or escalating pain, pus, red streaks, fever, blistering, darkening, skin breakdown, or feeling acutely unwell can require prompt local assessment. Widespread hives, wheezing, breathing difficulty, throat tightness, facial or tongue swelling, fainting, confusion, or rapidly developing whole-body symptoms are not routine local reactions and can require emergency care.
- Use emergency services for breathing or throat symptoms, facial or tongue swelling, fainting, severe confusion, or rapidly developing widespread hives or swelling.
- Seek prompt local assessment for rapid spread, severe or disproportionate pain, pus or drainage, red streaks, fever or chills, blistering, darkening, or skin breakdown.
- Contact the prescriber for persistent, recurrent, worsening, spreading, or treatment-limiting burning and before another injection or product decision.